Cure & Advancements/July 20, 2026/2 min read

New Research Explores How to Boost Insulin Sensitivity in Type 1 Diabetes

Scientists have identified a protein that enhances how the body uses insulin, and early lab work suggests a small peptide derived from it may help improve blood sugar control in Type 1 diabetes.

News report, corroborated with 1 indexed study

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cure researchbeta cellsadvancements

Key takeaways

Researchers found that a protein called ATG7 helps the body respond better to insulin by activating key signaling pathways in liver and muscle tissue.
A short peptide based on ATG7, called Aap2, showed promise in improving blood sugar control in mice with Type 1 diabetes in early laboratory studies.
This approach is separate from attempts to make muscles produce insulin through gene therapy and represents a different strategy for managing Type 1 diabetes.
These are early findings in animal models; human studies would be needed to determine if this approach could benefit people with Type 1 diabetes.

A New Target for Insulin Sensitivity

Researchers have identified an unexpected role for a protein called ATG7 in how the body's cells respond to insulin. Rather than acting through its previously known functions, circulating ATG7 directly enhances insulin sensitivity—the ability of cells to respond to and use insulin effectively.

The protein works by interacting with a key component of insulin signaling called IRS1, which sits inside cells and receives messages from insulin. When ATG7 activates IRS1, it sets off a chain reaction that helps cells take up glucose more efficiently. This crosstalk between the liver and muscle tissue appears to be central to maintaining good glucose balance.

A Peptide Shows Early Promise in Mice

Scientists extracted a small peptide from ATG7—a fragment called Aap2—and tested whether it could reproduce ATG7's insulin-sensitizing effects. In laboratory studies using mouse models of both Type 1 and Type 2 diabetes, Aap2 successfully improved how the animals' bodies handled glucose and controlled blood sugar levels.

The fact that the peptide worked in Type 1 diabetes models is noteworthy, since Type 1 involves autoimmune destruction of insulin-producing cells rather than insulin resistance alone. This suggests the approach might help Type 1 diabetes by making the remaining insulin the body produces work more effectively.

What This Means Right Now

These findings are early-stage research conducted in animal models. While the results are encouraging, much work remains before such an approach could be tested in people with Type 1 diabetes. Researchers would need to confirm the peptide's safety and efficacy in human studies and understand how it might be delivered to patients.

This research also highlights a complementary approach to other emerging strategies being explored for Type 1 diabetes—rather than attempting to make new insulin-producing cells or restore the immune system, this work focuses on helping the body use whatever insulin is available more efficiently.

Evidence label

Origin: Diabetes In Control (News report). Evidence: News report, corroborated with 1 indexed study. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.